| 体内研究: |
H2L5186303 (0-50 mg/kg,腹腔注射,单次剂量) 在 OVA 致敏小鼠中抑制嗜酸性粒细胞和淋巴细胞水平,具有气管炎症抑制作用。 H2L5186303 (10 mg/kg,腹腔注射,每隔一天注射三次,6 天) 在 Lpar5f/f Villin-Cre 小鼠肠隐窝中抑制细胞增殖,促进细胞凋亡。 |
| 参考文献: |
1. Fells JI, et al. Structure-based drug design identifies novel LPA3 antagonists. Bioorg Med Chem. 2009 Nov 1;17(21):7457-64. 2. Ye-Ji Lee, et al. Efficacy Comparison of LPA2 Antagonist H2L5186303 and Agonist GRI977143 on Ovalbumin-Induced Allergic Asthma in BALB/c Mice. Int J Mol Sci. 2022 Aug 28;23(17):9745. 3. Zhongxing Liang, et al. Compensatory Upregulation of LPA2 and Activation of the PI3K-Akt Pathway Prevent LPA5-Dependent Loss of Intestinal Epithelial Cells in Intestinal Organoids. Cells. 2022 Jul 20;11(14):2243. 4. Ishimoto K, et al. Rapid establishment of highly migratory cells from cancer cells for investigating cellular functions. J Recept Signal Transduct Res. 2019 Jun;39(3):194-198. |
| 溶解性: |
DMSO: soluble25mg/mL, clear |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
0 ml |
0 ml |
0 ml |
| 5 mM |
0 ml |
0 ml |
0 ml |
| 10 mM |
0 ml |
0 ml |
0 ml |
| 50 mM |
0 ml |
0 ml |
0 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |